Reports Library Publication
Insight Consumer Healthcare North America July / August 2026
27th August 2026 by CHC Insight
1. Cough & Cold Mucinex 12HR Multi-Symptom launched in USA
2. Allergy Remedies Zyrtec now offers drug-free spray format
3. CCA Q&A Expert Insights on CCA trends
4. Innovation Round-up Tylenol with Naproxen approved by FDA
5. News Review P&G acquires Thorne
Order this report
Why buy this report?
"It was another difficult year for cough, cold & allergy remedies as seasonal factors limited demand; sales declined in the retail channel, although e-commerce remained robust as more consumers embrace the convenience of home delivery. While there’s nothing marketers can do about cold & flu incidence or pollen counts, they can innovate to make their portfolios more attractive in the tough environment, and we cover several great examples in the issue, most notably Reckitt’s Mucinex 12HR Multi-Symptom and Kenvue’s Allergen Shield drug-free nasal spray, both of which bring something new to these well-established categories."
Nicholas Hall